We are constantly monitoring new technology developments and spend substantial time and resources to actively maintain and further strengthen the patent portfolio of our technology platforms and products.
We strive to protect our intellectual property around the world. Our patent portfolio is currently comprised of more than 250 patent applications with about 150 patents granted in more than 20 different countries/states including all major markets such as United States, Canada, Europe, Japan and China.
Products in our pipeline are protected by several layers combining platform and product patents and extending protection beyond 2035. We have exclusive worldwide license agreements for our two main products, DPX-Survivac and DPX-RSV.
Working at IMV brings you to the forefront of cutting-edge science and research for cancer and other serious diseases. We’ve worked hard to build a culture of innovation and collaboration.Learn more about life at IMV